# RGCC International

Source: https://onco.cc/companies/rgcc-international/  
OnCo record `rgcc-international` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RGCC offers blood tests that isolate circulating tumour cells and profile them to guide treatment choices and to track disease over time, sold worldwide to patients as well as physicians.

## Summary

RGCC International markets liquid biopsy tests based on circulating tumour cells: molecular profiling of the cells to suggest which drugs and natural substances might act on them, and serial counts to monitor disease activity and treatment response. Future of Cancer Care Today lists it as worldwide and patient- or physician-ordered. The tests sit outside mainstream guideline practice, and readers should weigh the evidence for chemosensitivity testing on circulating cells accordingly.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: RGCC Group
- Tags: ctgov-sponsor; fcct-directory
- HQ: Zug, Switzerland
- Type: diagnostics
- Website: https://rgcc-international.com/

## Sources

- Official website: https://rgcc-international.com/
- Listed on Future of Cancer Care Today (Sijbrandij Foundation): https://sijbrandijfoundation.org/fcct

## Connected records

- technologies: [Circulating tumour cell capture](https://onco.cc/technologies/ctc-capture/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)

---
JSON: https://onco.cc/api/v1/entities/rgcc-international.json